Genestreti Giovenzio, Di Battista Monica, Cavallo Giovanna, Bartolotti Marco, Brandes Alba A
Department of Medical Oncology, Azienda USL, Bellaria Hospital - IRCCS Institute of Neurological Sciences, Bologna, Italy.
Expert Rev Anticancer Ther. 2015;15(7):839-46. doi: 10.1586/14737140.2015.1052410. Epub 2015 May 31.
Several randomized trials have investigated the role of maintenance treatment for patients with advanced non-small cell lung cancer (NSCLC) not progressed after completion of first-line chemotherapy, with good performance score (PS) and no persistent chemotherapy-induced toxicity. Two separate strategies have been developed: the immediate use of non-cross-resistant drug (switch maintenance or early second-line therapy) or the continuation of platinum partner alone (continuation maintenance) or in combination with other drug (combination maintenance). Here we discuss how the benefits demonstrated in these studies may change clinical practice (in terms of potential toxicity and costs) and reflect on factors that may identify subgroups of patients who might benefit from maintenance therapy in general, and which maintenance therapy specifically.
多项随机试验研究了维持治疗对一线化疗完成后未进展、体能状态评分（PS）良好且无持续化疗所致毒性的晚期非小细胞肺癌（NSCLC）患者的作用。现已形成两种不同策略：立即使用非交叉耐药药物（转换维持或早期二线治疗），或单独继续使用铂类药物（持续维持）或与其他药物联合使用（联合维持）。在此，我们讨论这些研究中所证明的益处如何改变临床实践（就潜在毒性和成本而言），并思考可能识别出一般而言可能从维持治疗中获益的患者亚组以及具体哪种维持治疗的因素。
